Savior LLC’s Relmada Therapeutics RLMD Stock Holding History

Savior LLC’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,500	Closed	-$10.5K	–	86
2023 Q3	$10.5K	Hold	3,500	–	–	0.07%	60
2023 Q2	$8.61K	Hold	3,500	–	–	0.03%	68
2023 Q1	$7.91K	Hold	3,500	–	–	0.01%	96
2022 Q4	$12.2K	Hold	3,500	–	–	0.01%	95
2022 Q3	$130K	Hold	3,500	–	–	0.12%	43
2022 Q2	$66K	Hold	3,500	–	–	0.06%	47
2022 Q1	$91K	Hold	3,500	–	–	0.07%	50
2021 Q4	$76K	Hold	3,500	–	–	﹤0.01%	54
2021 Q3	$92K	Hold	3,500	–	–	0.09%	45
2021 Q2	$112K	Hold	3,500	–	–	0.09%	88
2021 Q1	$123K	Buy	+3,500	New	+$122K	0.12%	74

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Savior LLC's RLMD Position: Q4 2023 in Review

Savior LLC sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 3,500 shares — an estimated $10.5K sold.

Savior LLC first reported a position in RLMD in Q1 2021 and held it in 11 quarters. The position peaked at $130K in Q3 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

Savior LLC reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
Savior LLC sold 3,500 Relmada Therapeutics shares in Q4 2023, an estimated $10.5K.
Savior LLC first reported a position in Relmada Therapeutics in Q1 2021 and held it in 11 quarters.
Savior LLC's Relmada Therapeutics position peaked at $130K in Q3 2022.
83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Savior LLC's 13F filing for Q4 2023, filed 1 Feb 2024.